Tectonic Therapeutic is a clinical-stage biotechnology company that specializes in the discovery and development of therapeutic proteins and antibodies aimed at modulating G-Protein Coupled Receptors (GPCRs). GPCRs are crucial receptor molecules that facilitate communication between cells and their environment, playing a significant role in various biological processes such as blood pressure regulation and immune response. Tectonic has developed a proprietary technology platform known as GEODe™, which is designed to address the challenges associated with GPCR-targeted biologic medicines. This platform aims to enhance the discovery and development of novel therapies, particularly in areas with significant unmet medical needs, where existing treatment options are limited or absent.

The company's focus on biologics, particularly antibodies, allows for greater selectivity when targeting specific GPCRs, which can optimize therapeutic efficacy and safety. Tectonic's approach includes the development of bispecific proteins that can engage multiple targets simultaneously, a capability that small molecules typically lack. With a strong foundation in the biochemistry and biophysics of GPCRs, Tectonic is well-positioned to translate basic research into innovative therapies that can improve patient outcomes in various disease areas.

United States

Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs). With our proprietary GEODe™ platform, we are targeting the most difficult, previously undruggable receptors in the class, aiming to unlock their therapeutic utility to develop new treatments for a broad range of patients with important unmet needs.

Tectonic Therapeutic

Company Details